Greenspan E M, Bruckner H W
Natl Cancer Inst Monogr. 1975 Oct;42:173-5.
Twenty-two patients were treated for bulky stage IIIb and/or stage IV ovarian cancer with methotrexate (MTX), triethylenethiophosphoramide (thio-TEPA), or combination of the two. Two cycles of MTX 3 weeks apart failed to result in any important tumor shrinkage in 9 to 10 patients; thio-TEPA, in contrast, produced a rapid objective tumor regression in 8 of 12 patients. In addition, 4 of 8 patients who had not responded to MTX showed greater than 50% objective tumor regression during the first 4 weeks after crossover to thio-TEPA. The kinetics or drug penetration factor of the cell cycle-specific agent (MTX) in two oral cycles was of no clinical value alone in bulky ovarian cancer.
22例Ⅲb期和/或Ⅳ期晚期卵巢癌患者接受了甲氨蝶呤（MTX）、塞替派（thio-TEPA）或二者联合治疗。9至10例患者间隔3周接受两个周期的MTX治疗后，肿瘤未出现明显缩小；相比之下，12例患者中有8例接受thio-TEPA治疗后肿瘤迅速出现客观消退。此外，8例对MTX无反应的患者中，有4例在换用thio-TEPA后的前4周内肿瘤客观消退超过50%。在晚期卵巢癌中，细胞周期特异性药物（MTX）两个口服周期的动力学或药物渗透因子单独使用无临床价值。
